Phaseline

Companies › IO Biotech

IO Biotech: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 3; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IO102-IO103
Dual peptide antigen cancer vaccine (IDO peptide antigen IO102 and PD-L1 peptide antigen I
IDO1, CD274Phase 3Metastatic MelanomaSep 2027
IO102
IDO1 peptide
IDO1Phase 2MelanomaJan 2027
IO103
PD-L1 peptide
CD274Phase 2MelanomaJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05280314IO102Phase 2MelanomaOncologyJan 2027
NCT05280314IO103Phase 2MelanomaOncologyJan 2027
NCT05155254IO102-IO103Phase 3Metastatic MelanomaOncologySep 2027

Targets

IDO1 (2) CD274 (2)

Companies with the same targets

AstraZeneca Pfizer ImmuneOncia Therapeutics Akeso Roche Biotheus Suzhou Suncadia Biopharmaceuticals Shine-On Biomedical 3D Medicines (Sichuan) Shanghai Henlius Biotech

Companies built like this

Seattle Project CellCentric Criterium Tesaro iOnctura

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.